<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335839</url>
  </required_header>
  <id_info>
    <org_study_id>STRIVE.2017</org_study_id>
    <nct_id>NCT03335839</nct_id>
  </id_info>
  <brief_title>Adjunctive, Low-dose tPA in Primary PCI for STEMI</brief_title>
  <acronym>STRIVE</acronym>
  <official_title>Adjunctive, Low-dose Intracoronary Recombinant Tissue Plasminogen Activator (tPA) Versus Placebo for Primary PCI in Patients With ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen
      activator during primary percutaneous coronary intervention (PCI) for patients with ST
      elevation myocardial infarction (STEMI) in reducing major adverse cardiovascular events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STRIVE is a prospective, 3-arm, parallel group, open label, randomized controlled trial
      evaluating the efficacy of a novel approach to prevent and treat microvascular obstruction
      and reduce major cardiovascular events using intracoronary administration of very low-dose
      fibrinolytic (tissue plasminogen activator, tPA) directly into the culprit coronary artery
      during primary PCI.

      The objective is to determine if low-dose adjunctive intracoronary tPA (10 mg or 20 mg) will
      reduce the incidence of cardiovascular death, myocardial infarction, or new onset heart
      failure in patients undergoing primary PCI for STEMI.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>180 days</time_frame>
    <description>Composite of cardiovascular death, myocardial re-infarction or new onset heart failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete ST-segment resolution</measure>
    <time_frame>30 minutes</time_frame>
    <description>Complete (≥70%) ST-segment resolution (worst lead) at 30 minutes post-PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>180 days</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset heart failure</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Intracoronary tPA 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intracoronary tPA 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tissue plasminogen activator</intervention_name>
    <description>Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.</description>
    <arm_group_label>Intracoronary tPA 10 mg</arm_group_label>
    <arm_group_label>Intracoronary tPA 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with STEMI undergoing primary PCI and,

          2. ECG changes indicating large territory STEMI (defined as ≥2mm ST-segment elevation in
             2 contiguous anterior precordial leads; or ≥2mm ST-segment elevation in 2 inferior
             leads coupled with ST-segment depression in 2 contiguous anterior leads for a total
             ST-segment deviation of ≥8mm) and,

          3. Randomization ≤ 6hrs of symptom onset and,

          4. Large thrombus burden with angiographic TIMI Thrombus Grade ≥3

        Exclusion Criteria:

          1. Active internal bleeding or high risk of bleeding or any prior intracranial bleeding

          2. Any other absolute or relative contraindication to fibrinolytic therapy

          3. Administration of a fibrinolytic ≤24hrs prior to randomization

          4. Cardiogenic shock

          5. Left bundle branch block (excluded because the ECG cannot be evaluated for ST segment
             resolution, an outcome of the study)

          6. Planned upfront use of a glycoprotein IIb/IIIa inhibitor

          7. Any medical, geographic, or social factor making study participation impractical or
             precluding 6 month follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shamir Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University, Hamilton Health Sciences, Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandi Meeks, MSc</last_name>
    <phone>9055274322</phone>
    <email>strive@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine Brett, MSc</last_name>
    <phone>9055274322</phone>
    <email>strive@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>STRIVE Investigator</last_name>
      <phone>9055274322</phone>
      <email>strive@phri.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tPA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

